Restoring Safeguards for Dangerous Abortion Drugs Act
The Restoring Safeguards for Dangerous Abortion Drugs Act would (1) revert the safety framework for the abortion drug mifepristone (also known as Mifeprex, Korlym, RU-486) to the version approved in June 2011 and prevent any new or modified risk evaluation and mitigation strategy (REMS) for this drug, (2) create a federal civil liability regime that lets individuals sue “covered entities” (such as telehealth providers and pharmacies) for harms they allege come from mifepristone when the drug is imported or transported illegally, and (3) bar importation of mifepristone into the United States, including mail-order shipments. The bill would impose a 90-day deadline after enactment to implement the REMS reversion and would allow private lawsuits for damages, penalties, and legal fees. In short, it aims to lock in an older safety regime for mifepristone, expand legal accountability for harms linked to the drug, and prohibit its importation. Potential impact includes reduced access to mifepristone via telemedicine or mail-order channels, increased legal exposure for providers and others involved with the drug’s distribution, and a higher barrier to bringing mifepristone into the U.S. market. These provisions interact with ongoing debates over abortion access, drug safety regulation, and interstate commerce.